Newsroom

Download PDF CAMBRIDGE, MA, January 3, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of Kenneth M. Bate, president and chief executive officer of NitroMed, Inc., to its Board of Directors. “We are very pleased to welcome

Download PDF CAMBRIDGE, MA, January 2, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals, is scheduled to present at the 26th   Annual JPMorgan Healthcare Conference on Tuesday, January 8, 2008 at 2:30 p.m. PT at the Westin St. Francis Hotel in San Francisco. About AVEO AVEO is

Download PDF – Agreement Highlights Growing Interest in Novel Biology Platform that Identifies Clinical Response of Cancer Drugs- CAMBRIDGE, MA, December 4, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it has signed a collaborative agreement with Eli

Download PDF CAMBRIDGE, MA, November 20, 2007 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals, is scheduled to present at the Lazard Capital Markets 4th Annual Healthcare Conference on Tuesday, November 27, 2007 at 9:30 a.m. ET at The New York Palace Hotel in New York City. About

Download PDF AV-412 Has Potential to Address Drug Resistance in Non-Small Cell Lung and Breast Cancer CAMBRIDGE, MA, November 13, 2007 – AVEO Pharmaceuticals, Inc., today announced encouraging preclinical data that show the potential of AV-412, a novel next generation oral tyrosine kinase inhibitor, as a therapeutic agent for the treatment of drug-resistant cancers expressing

Download PDF Company Initiates Phase 2 Clinical Trial of AV-951 in Patients with RCC Cambridge, MA, November 6, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced positive results from an expanded Phase 1 clinical trial of its lead product

Download PDF CAMBRIDGE, MA, November 1, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of David Johnston to the newly created position of Chief Financial Officer.  “As we continue to expand our pipeline of targeted cancer therapies,

Download PDF CAMBRIDGE, MA, October 30, 2007 – AVEO Pharmaceuticals, Inc., today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals is scheduled to present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Tuesday, November 6, 2007 at 9:50 a.m. ET at The New York Palace Hotel in New York